CRLF1

Across TCGA pan-cancer cohorts, CRLF1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CRLF1 data layer compared with 18 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher CRLF1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CRLF1 expression acts as an unfavorable survival marker.

PRAD and SKCM are the cancer types where CRLF1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	OS	Median	All	0.491	0.893	<.001	8	view →
SKCM	DFS	Median	III,IV	0.184	0.615	.017	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CRLF1–PRAD (OS)

Open the PRAD breakdown →